LivaNova to Present Autonomic Regulation Therapy Findings for Heart Failure During European Society of Cardiology Congress 2020
In a novel therapeutic approach, the LivaNova VITARIA® System delivers ART via mild electrical impulses applied to the right vagus nerve to increase parasympathetic activity in ways that improve regulation of cardiovascular function, including electrophysiological stability, in patients with advanced heart failure. The ANTHEM-HF clinical study (NCT01823887) reported improved baroreceptor sensitivity (heart rate turbulence or HRT), heart rate variability (rMSSD) and reduced cardiac electrical instability (T-wave alternans or TWA) after 12 months of chronic vagus nerve stimulation. However, it remained unknown whether these benefits persist beyond one year.
“With more than 25 million people worldwide suffering from heart failure, it is crucial that we find improved methods to treat this complex syndrome,” said
In lieu of traditional in-person presentations, ESC will publish all e-posters accepted for presentation on
“Multi-Year Improvement in Autonomic Tone, Baroreceptor Sensitivity and Cardiac Electrical Stability Using Vagus Nerve Stimulation in Patients with HFrEF in the ANTHEM-HF Study”
The VITARIA System received CE Mark approval in 2015 and has been approved by the
To learn more about the LivaNova VITARIA System and the treatment of heart failure with ART, visit www.ARTforHeartFailure.com.
About
For more information, please visit www.livanova.com.
Safe Harbor Statement
This news release contains “forward-looking statements” concerning our goals, beliefs, expectations, strategies, objectives, plans and underlying assumptions and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding ART and our approach to treating heart failure by delivering ART using vagus nerve stimulation. Actual results may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of our Annual Report on Form 10-K for the year ended
View source version on businesswire.com: https://www.businesswire.com/news/home/20200812005238/en/
LivaNova PLC Media Contact
VP, Corporate Communications
Corporate.Communications@livanova.com
Source: